Keyword: lungcancer
-
A comprehensive review by an international consortium of scientists has raised serious concerns about the COVID-19 mRNA vaccines’ safety profile. Review articles are summaries of current research on a particular topic. They are also sometimes called literature reviews or secondary sources. The review, “N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?” published on Science Direct, delves into the potential implications of a vaccine ingredient—N1-methyl-pseudouridine (m1Ψ)—that may play a role in immune suppression and cancer proliferation. m1Ψ was incorporated into Pfizer-BioNTech’s COVID-19 mRNA vaccine to enhance its efficacy. This component was introduced in the mRNA vaccine as a means to produce a...
-
Yesterday the Expose published an article which highlighted just a few of the various diseases that were found to be potentially caused by parasites, including cancers. A recent review of nine published research papers by Doctor William Makis further supports the views in the article, but Dr Makis is more qualified to say “it is a reasonable hypothesis that COVID-19 mRNA Vaccine Turbo Cancer patients could benefit significantly from anti-parasitic drugs.” One anti parasitic drug in particular, Fenbendazole, however, has not been sanctioned for human use by the FDA, but despite lacking “official” approval, it is cheap, safe and more...
-
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial. The AEGEAN trial evaluated durvalumab given perioperatively, meaning therapy is given both before and after surgery. Participants on the trial received either pre-surgical (neoadjuvant) durvalumab and platinum-based chemotherapy followed by post-surgical (adjuvant) durvalumab or neoadjuvant placebo and chemotherapy followed by adjuvant placebo. Of the patients receiving perioperative durvalumab, 17.2% had a pCR compared to just 4.3% of...
-
Researchers are testing a drug against obesity and diabetes, and now a team reports that substance has a beneficial effect on mice with experimental lung cancer. The substance is the short-chain fatty acid propionate, which is naturally produced by bacteria in our gut. This new research study shows that treating mice with lung cancer with propionate can reduce the occurrence of metastases. The study also demonstrates a role for propionate in increasing the effectiveness of Cisplatin, a commonly used drug for lung cancer patients. One of these programs is called EMT (epithelial-mesenchymal transition), which existed even when we were still...
-
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers. The multicenter, randomized Phase II NeoCOAST clinical trial evaluated neoadjuvant durvalumab alone and in combination with each of the following novel immunotherapies: the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, and the anti-STAT3 antisense oligonucleotide danvatirsen. The NeoCOAST study enrolled 84 patients with untreated, resectable (>2cm), stage I-IIIA NSCLC. Eighty-three patients received one 28-day cycle of neoadjuvant durvalumab alone or combined with another therapy. The investigators assessed pathological complete...
-
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research. The FLAURA2 study was led by Dr. Pasi A. Jänne from the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Mass. Osimertinib, a potent third-generation EGFR-TKI with central nervous system activity, has garnered attention for its targeted inhibition of both sensitizing and resistance EGFR mutations. According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs. The study enrolled 557 patients and...
-
Researchers from Johns Hopkins and the Risk Management Foundation of the Harvard Medical Institutions looked at 15 diseases and concluded that 371,000 Americans died and 424,000 were permanently disabled as a result of misdiagnoses. About 795,000 Americans die or are permanently disabled every year due to misdiagnosed medical conditions. A new analysis led by experts at Johns Hopkins Medicine in Baltimore looks more closely at diagnostic error and its impact. "Prior work has generally focused on errors occurring in a specific clinical setting, such as primary care, the emergency department or hospital-based care," lead author Dr. David Newman-Toker, director of...
-
Research has found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast. The researchers evaluated 20 randomized patients who took one of two daily alectinib doses with either low-fat yogurt alone, a full continental breakfast, or a lunch of their choosing. Taking alectinib with low-fat yogurt resulted in 14% less exposure than in the continental breakfast group, and 20% less than in those who took the medication with...
-
The FDA-approved lung cancer drug osimertinib (sold under the brand name Tagrisso) slashes the risk of death by 51% for certain patients whose cancer is caught early, according to new trial data. “This should be the new standard of care for these patients,” Nathan Pennell, co-director of the Cleveland Clinic Lung Cancer Program, who wasn’t involved in the drug’s development, said in a statement for the American Society of Clinical Oncology. The drug: Lung cancer is the second-most common cancer in the world, with 2.2 million new diagnoses every year. The vast majority fall into a category called “non-small cell...
-
A pill has been shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumor, according to clinical trial results. The treatment developed by the pharmaceutical group AstraZeneca is called osimertinib and is marketed under the name Tagrisso. It targets a particular type of lung cancer in patients suffering from so-called non-small cell cancer, the most common type, and showing a particular type of mutation. These mutations, on what is called the epidermal growth factor receptor, or EGFR, affect 10 percent to 25 percent of lung cancer patients...
-
Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, an important question has remained unanswered: How long should a patient with advanced non-small cell lung cancer (NSCLC), who receives immunotherapy as part of their initial treatment, continue with treatment? A new retrospective cohort study suggests that it's reasonable to stop immunotherapy treatment at two years as long as their cancer hasn't progressed. The researchers found no statistically significant difference in overall survival between patients who stopped treatment...
-
More patients are choosing radiation therapy over surgery to treat their early-stage lung cancer, but a new study argues they might be making a mistake. People who are good surgical candidates for lung cancer appear to have a five-year survival rate that's 15 percentage points lower if they opt to have radiation treatment instead, according to findings. Said Dr. Brooks Udelsman: "If you have a patient who is expected to live more than two years, they're probably going to benefit from the surgery." The data included about 24,700 patients whose tumors were surgically removed and nearly 6,000 who underwent targeted...
-
One of the newest types of cancer drugs, immunotherapies called immune checkpoint inhibitors, has transformed the treatment of lung cancer over the last decade—dramatically improving the survival of some patients with the most common form of this disease, non-small cell lung cancer (NSCLC). However, only about 20% of patients experience a benefit. A new study reveals key molecular features of lung tumors that could explain why some patients respond to these treatments while others do not. The team has pinpointed factors that may influence the response of NSCLC patients to immunotherapies that inhibit the PD-1 or PD-L1 proteins. The PD-1/PD-L1...
-
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented by researchers. The AEGEAN trial evaluated durvalumab given perioperatively, meaning therapy is given both before and after surgery. Participants on the trial received either pre-surgical (neoadjuvant) durvalumab and platinum-based chemotherapy followed by post-surgical (adjuvant) durvalumab or neoadjuvant placebo and chemotherapy followed by adjuvant placebo. "Throughout decades of research with adjuvant and neoadjuvant chemotherapy, we only succeeded in increasing...
-
The traditional treatment for early-stage non-small cell lung cancer is a lobectomy, where a surgeon eradicates cancerous tissue by removing an entire lung lobe. Yet, new research finds that select patients with early-stage disease who undergo a less invasive procedure have comparable outcomes. The 10-year study adds evidence that supports a new standard to preserve lung tissue in cancer patients whenever possible. 697 patients with peripheral stage 1 tumors less than 2 centimeters in size were randomly assigned to undergo a lobectomy or a sublobar resection, where part of the cancerous lobe is removed. In the latter, patients received either...
-
In a Phase II trial, adding ipilimumab to a pre-surgical combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC). New findings from the NEOSTAR trial provide further support for neoadjuvant immunotherapy-based treatment as an approach to reduce viable tumor at surgery and to improve outcomes in NSCLC. The combination also was associated with an increase in immune cell infiltration and a favorable gut microbiome composition. The current study reports on the latest two arms of the NEOSTAR trial, evaluating neoadjuvant nivolumab plus...
-
Lung cancer is currently the third most common type of cancer in the U.S. A new double lung transplant technique was successful for two patients with lung cancer, Northwestern Medicine announced. The hospital said it's leveraging that success into a new clinical program that will offer transplants to patients with end-stage lung cancer. "Every morning when I open my eyes, like, I just can't believe it, and life has different meaning now," said Tannaz Ameli, the second person with lung cancer to receive the transplant, during a press briefing. Lung cancer is currently the third most common type of cancer...
-
Tagrisso (osimertinib) nearly doubles disease-free survival in earlier-stage patients whose lung cancer is driven by a mutation in their EGFR (epidermal growth factor receptor) gene, researchers report. After four years of follow-up, disease-free survival was 73% in the Tagrisso group versus 38% in patients who received a placebo, updated results showed. The drug also cut patients' cancer recurrence in half compared to placebo, 27% versus 60%. In addition, patients were less likely to develop cancers in other parts of the body. "One of the main benefits of this drug is that it has good brain penetration and it's a whole-body...
-
Primary lung neuroendocrine tumors are very rare tumors that represent about 1-2% of all lung cancer cases. The common treatment for early stage lung neuroendocrine tumors is surgery, but that is not an option for all patients. In a new article, Daniel Oliver, M.D. shows that stereotactic body radiotherapy, or SBRT, is an effective treatment for patients with early stage lung neuroendocrine tumors. SBRT is a treatment approach that delivers high doses of radiation to precise areas of a tumor, minimizing damage to surrounding normal cells. Patients receiving SBRT often have less toxicity and side effects compared to treatment with...
-
A team has found a mechanism of recruitment for tumor-associated cells (cancer-associated fibroblasts or CAFs), which are essential to lung adenocarcinoma, the most frequent type of cancer. These cancer-associated cells contribute to all the phases of tumor development, including metastasis. The study reveals there is a type of inhibitor drug that could be useful against the migratory advantage of these cancer-associated cells, and so could prevent their recruitment and therefore their contribution to the tumor development. "Lung adenocarcinoma represents 40% of the cases of lung cancer and it produces an early metastasis," says Jordi Alcaraz. Alcaraz found in previous studies...
|
|
|